Clinical Trial: NCT05074810
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | Verastem, Inc. |
| Information Provided By: | Verastem, Inc. |
| Last Update Posted: | 2026-01-12 |
Study Overview
Brief Summary
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.
Official Title
A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)
Conditions
Non Small Cell Lung Cancer, KRAS Activating Mutation
Intervention / Treatment
- Drug: avutometinib and sotorasib
- Drug: avutometinib and sotorasib and defactinib
Other Study ID Numbers
- VS-6766-203
Start Date (Actual)
2022-04-12
Primary Completion Date (Estimated)
2026-06
Study Completion Date (Estimated)
2027-04
Enrollment (Estimated)
153
Study Type
Interventional
Phase
Phase 1, Phase 2
| Lead Sponsor: | Verastem, Inc. |
| Information Provided By: | Verastem, Inc. |
| Last Update Posted: | 2026-01-12 |
Study Overview
Brief Summary
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.
Official Title
A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)
Conditions
Non Small Cell Lung Cancer, KRAS Activating Mutation
Intervention / Treatment
- Drug: avutometinib and sotorasib
- Drug: avutometinib and sotorasib and defactinib
Other Study ID Numbers
- VS-6766-203
Start Date (Actual)
2022-04-12
Primary Completion Date (Estimated)
2026-06
Study Completion Date (Estimated)
2027-04
Enrollment (Estimated)
153
Study Type
Interventional
Phase
Phase 1, Phase 2